LISCure
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sinsa-dong Mi Tower Fl 7, Gangnam-daero,...Phone Number
+82 317061710Website
liscure.bioRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
2
About LISCure
LISCure Biosciences was established to develop a "bacteria-mediated immunotherapy" that can treat patients by itself or be used in combination with other drugs for major indications such as tumors, neurological degeneration, autoimmune, and metabolic diseases. This company was established in 2018, and is headquartered in Seoul, Korea.Explore more
LISCure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LISCure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
LISCure, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on LISCure recently announced quarterly report
Funding: Get notified immidiatlly once LISCure has new funding data
Click to see if LISCure had a recent Job posting/layoffs
Product Launch: Get notified when LISCure launches new products
Check if LISCure has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at LISCure
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if LISCure is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined LISCure as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
LISCure is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
LISCure is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about LISCure.
LISCure financials insights
Gather financial insights about LISCure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$1.8M
2021
Series B
$21M
LISCure Tech Stack
A closer look at the technologies used by LISCure
See more technologies
Most Recent Scoops
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Open Position
Funding
Funding
LISCure News & Media
LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading global pharmaceutical company for its proprietary blood-brain barrier (BBB) shuttle platform, ExoPN-101. This marks LISCure's fourth MTA, further validating the technological innovation and commercial potential of the ExoPN-101 platform in the global marketLISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Cholangitis (PSC), a rare and progressive liver disease with no approved treatments on November 5 (local time in the U.S.). LB-P8: A First in Class Candidate Targeting the Gut-Liver axis PSC is a cholestatic liver disease of unknownLISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient
SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This...LISCure BioSciences Secures World's First FDA NDI notification for Hair Health Probiotic Mobiome®
SEOUL, South Korea, Sept. 9, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") today announced that Mobiome®, its proprietary hair health probiotic, has received New Dietary Ingredient (NDI) Notification from the U.S. Food and Drug Administration (FDA) —the first such recognition worldwide for targeting hair health. Mobiome® had previously been approved by the Korean Ministry of Food and Drug Safety (MFDS) as a new functional ingredient, based on extensive scientific validation in both precli
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding LISCure
Sign Up For FreeTo access detailed company insights
LISCure Biosciences was established to develop a "bacteria-mediated immunotherapy" that can treat patients by itself or be used in combination with other drugs for major indications such as tumors, neurological degeneration, autoimmune, and metabolic diseases. This company was established in 2018, and is headquartered in Seoul, Korea.... Read More
